Management of postmenopausal osteoporosis: position statement of The North American Menopause Society

Gallagher, John C.; Ettinger, Bruce; Gass, Margery; Kagan, Risa; McClung, Betsy Love; McClung, Michael R.; Simon, James A.

doi:10.1097/00042192-200203000-00003

Cited by 38 publications

(6 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…consumption as part of the life style modifications to prevent osteoporosis. 15 The beneficial effects of physical activity and weight bearing exercises have been well documented. [16][17][18] Chemotherapeutic agents for treatment of osteoporosis and oral bone loss: Several pharmacological agents are available to increase bone mineral density and therefore treat or prevent osteoporosis.…”

Section: Introductionmentioning

confidence: 99%

Osteoporosis and Periodontal Disease: Association and Mechanisms: An in-Depth Review

Bodduru¹,

Deshmukh²,

Chintawa³

et al. 2016

IJTA

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Osteoporosis and Periodontal Disease: Association and Mechanisms: An in-Depth Review

Bodduru¹,

Deshmukh²,

Chintawa³

et al. 2016

IJTA

View full text Add to dashboard Cite

“…Комментарий: Согласно всем проведенным исследованиям, рентгеновская денситометрия является наиболее точным методом мониторинга терапии, доказавшим связь изменений на фоне терапии со снижением риска переломов при применении зарегистрированных препаратов для лечения остеопороза, поэтому этот метод используется для динамического контроля, но не чаще 1 раза в 12 месяцев [123].…”

Section: уровень убедительности рекомендаций в (уровень достоверности доказательств -3)unclassified

Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis

Belaya

Belova²,

Biryukova

et al. 2021

Osteopor Bone Dis

View full text Add to dashboard Cite

Due to continuous aging of population and increase in the number of elderly people, osteoporosis became socially significant disease leading to disability, increasing mortality and thereby putting an additional burden on the public healthcare system.Screening to identify groups with a high probability of fracture is recommended using the FRAX® Tool for all postmenopausal women and men over 50 years old (А1). In the presense of major pathological fractures (hip, spine, multiple fractures) it is recommended to diagnose osteoporosis and prescribe treatment regardless of the results of spine and hip double X-ray absorptiometry (DXA) or FRAX® (B2).It is recommended to evaluate C-terminal telopeptide when prescribing antiresorptive therapy and procollagen type 1 N-terminal propeptide (P1NP) when prescribing anabolic therapy to patients receiving osteoporosis treatment at baseline and 3 months after the start of therapy in order to assess the effectiveness of treatment early and adherence to the therapy (А2). It is recommended to diagnose osteoporosis and prescribe treatment to patients with high individual 10-year probability of major pathological fractures (FRAX®) regardless of the results of spine and hip DXA (В3).It is recommended to diagnose osteoporosis and prescribe treatment with a decrease in BMD, measured by DXA, by 2.5 or more T-score standard deviations in femoral neck, and/or in total hip, and/or in lumbar vertebrae, in postmenopausal women and men over 50 years old (А2).It is recommended to prescribe bisphosphonates, denosumab or teriparatide to prevent pathological fractures and increase BMD in patients with postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis (А2). When the clinical effect of therapy in osteoporotic patients without pathological fractures is achieved (BMD T-score > -2.0 SD in femoral neck and absence of new fractures), it is recommended to interrupt bisphosphonates therapy for 1-2 years with subsequent follow-up (B2). In patients with vertebral fractures, hip fractures or multiple fractures, it is recommended to continue ceaseless long-term treatment of osteoporosis (В3).All drugs for the treatment of osteoporosis are recommended to be prescribed in combination with calcium and cholecalciferol (А2). In order to reduce the risk of recurrent fractures by prescribing osteoporosis therapy timely and maintaining long-term follow-up of patients over 50 years old with pathological fractures, it is recommended to create Fracture Liaison Services (В2).

show abstract

“…Комментарии. Скрининг всех женщин, находящихся в периоде постменопаузы, с использованием рентгеновской денситометрии экономически нецелесообразен, поскольку в 2-10 раз превышает стоимость лечения всех низкотравматических переломов, поэтому единственной разумной стратегией является селективный скрининг в группах риска [38]. Ранее существовал широкий спектр показаний для проведения рентгеновской денситометрии аксиального скелета.…”

Section: ограничения Fraxunclassified

“…Однако в настоящее время ключевые факторы риска переломов сведены в алгоритм FRAX и могут быть оценены через ресурс, доступный в сети Интернет. Рентгеновскую денситоме- Возраст, годы 10-летняя вероятность переломов, % точка терапевтического вмешательства 1 низкая вероятность переломов 2 высокая вероятность переломов 3 [38].…”

Section: ограничения Fraxunclassified

“…Все расчеты и градации риска переломов построены на относительных показателях: стандартных отклонениях от референсной базы данных молодых здоровых женщин (пика костной массы). Референсные данные МПК были получены для определенных зон скелета с применением установленной укладки [37][38][39][40][41][42][43]. Эти нормы не являются референсными для других зон скелета и других укладок.…”

Section: ограничения Fraxunclassified

See 1 more Smart Citation

Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis

Афанасьевна¹,

Евгеньевна²,

Яковлевна³

et al. 2018

Probl Endokrinol (Mosk)

View full text Add to dashboard Cite

Screening using the Fracture Risk Assessment Tool (FRAX) is recommended in all postmenopausal woman and mеn over 50 (A1) in order to identify individuals with high probability of fractures. It is recommended to diagnose osteoporosis and start treatment in patients with fragility fracture of large bones of the skeleton and/or high individual probability of major fragility fractures (FRAX) and/or detected decrease in bone mineral density (BMD) up to –2.5 T-score as assessed by DXA in the femoral neck and/or lumbar vertebrae (A1). Patients with back pain, lifetime height loss of 4 cm or height loss of 2 cm since a previous medical examination, those who receive glucocorticoids, patients with long lasting decompensated type 2 diabetes mellitus, or those receiving insulin therapy, as well as patients who were previously diagnosed with fragility fractures at the other sites are advised to underwent standard lateral X-ray imaging of the spine (Th4—L5) in order to verify the presence of compression vertebral fractures (B1). Dual-energy X-ray absorptiometry (DXA) is recommended for individuals whose 10-year probability of major osteoporotic fracture (FRAX) falls within the medium risk group (B1). It is recommended to include the trabecular bone score (TBS) the FRAX algorithm in order to improve the sensitivity of this method (B1). Laboratory testing is recommended for the differential diagnosis with other causes of increased skeletal fragility in all patients with newly diagnosed osteoporosis and when previously prescribed antiosteoporostic treatment was ineffective (B1). Bisphosphonates (BPs), antibodies to receptor activator of nuclear factor kappa-beta ligand (RANKL) (denosumab), or parathyroid hormone analogue (teriparatide) are equally recommended to prevent fragility fractures and increase BMD in patients with osteoporosis (A1). Denosumab is also recommended to prevent BMD loss and fractures in females receiving aromatase inhibitors therapy for breast cancer and males with prostate cancer receiving hormone-deprivation therapy and having no bone metastases (A1). Since teriparatide has the anabolic effect, it is recommended as the first line treatment in patients with severe osteoporosis having history of vertebral fractures, in the individuals with very high risk of fragility fractures, or in the cases when antiresorptive treatment was ineffective (B1). All medications for treatment of osteoporosis are recommended in combination with calcium and vitamin D supplements (A1).

show abstract

Management of postmenopausal osteoporosis: position statement of The North American Menopause Society

Cited by 38 publications

References 58 publications

Osteoporosis and Periodontal Disease: Association and Mechanisms: An in-Depth Review

Osteoporosis and Periodontal Disease: Association and Mechanisms: An in-Depth Review

Federal clinical guidelines for diagnosis, treatment and prevention of osteoporosis

Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis

Contact Info

Product

Resources

About